WuXi Biologics (Cayman) Inc.

OTCPK:WXIB.F Stock Report

Market Cap: US$9.2b

WuXi Biologics (Cayman) Valuation

Is WXIB.F undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of WXIB.F when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: WXIB.F ($2.17) is trading below our estimate of fair value ($3.06)

Significantly Below Fair Value: WXIB.F is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for WXIB.F?

Key metric: As WXIB.F is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for WXIB.F. This is calculated by dividing WXIB.F's market cap by their current earnings.
What is WXIB.F's PE Ratio?
PE Ratio25.6x
EarningsCN¥2.63b
Market CapCN¥67.31b

Price to Earnings Ratio vs Peers

How does WXIB.F's PE Ratio compare to its peers?

The above table shows the PE ratio for WXIB.F vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average39.5x
MEDP Medpace Holdings
29.1x10.8%US$10.6b
BRKR Bruker
29x15.8%US$8.8b
CRL Charles River Laboratories International
23.1x12.1%US$9.5b
TECH Bio-Techne
77x21.2%US$11.6b
WXIB.F WuXi Biologics (Cayman)
25.6x17.1%US$71.7b

Price-To-Earnings vs Peers: WXIB.F is good value based on its Price-To-Earnings Ratio (25.6x) compared to the peer average (39.5x).

Price to Earnings Ratio vs Industry

How does WXIB.F's PE Ratio compare vs other companies in the US Life Sciences Industry?

1 CompanyPrice / EarningsEstimated GrowthMarket Cap
REPC.F RepliCel Life Sciences
0.07xn/aUS$325.01k
No more companies available in this PE range
WXIB.F 25.6xIndustry Avg. 36.5xNo. of Companies4PE020406080100+
1 CompanyEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: WXIB.F is good value based on its Price-To-Earnings Ratio (25.6x) compared to the Global Life Sciences industry average (36.2x).

Price to Earnings Ratio vs Fair Ratio

What is WXIB.F's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

WXIB.F PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio25.6x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate WXIB.F's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst WXIB.F forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$2.17
US$2.52
+15.9%
37.0%US$4.40US$1.25n/a24
Dec ’25n/a
US$2.42
0%
38.7%US$4.43US$1.26n/a25
Nov ’25US$2.25
US$2.50
+11.1%
39.8%US$4.50US$1.28n/a26
Oct ’25US$2.10
US$2.52
+19.8%
43.8%US$5.47US$1.30n/a26
Sep ’25US$1.32
US$2.47
+87.3%
44.8%US$5.41US$1.09n/a26
Aug ’25US$1.36
US$2.73
+100.9%
38.5%US$5.38US$1.09n/a25
Jul ’25US$1.38
US$2.90
+110.0%
44.9%US$6.81US$1.52n/a25
Jun ’25US$1.48
US$3.38
+128.7%
58.2%US$9.36US$1.53n/a26
May ’25US$1.63
US$3.64
+123.5%
55.3%US$9.36US$1.53n/a26
Apr ’25US$1.85
US$4.42
+139.2%
53.2%US$9.38US$1.53n/a28
Mar ’25US$2.41
US$6.56
+172.4%
33.9%US$14.99US$2.80n/a29
Feb ’25US$2.59
US$6.59
+154.4%
33.9%US$15.00US$2.80n/a29
Jan ’25US$3.71
US$6.80
+83.2%
34.6%US$15.09US$2.82n/a29
Dec ’24n/a
US$9.71
0%
19.9%US$15.06US$6.10n/a27
Nov ’24US$6.40
US$9.49
+48.3%
19.6%US$14.41US$5.97US$2.2527
Oct ’24US$5.63
US$9.88
+75.5%
23.8%US$17.32US$5.98US$2.1029
Sep ’24US$5.64
US$10.10
+79.0%
23.2%US$17.42US$6.02US$1.3229
Aug ’24n/a
US$10.40
0%
24.6%US$17.62US$3.83US$1.3629
Jul ’24US$4.90
US$10.43
+112.8%
23.5%US$17.43US$3.79US$1.3829
Jun ’24US$5.44
US$11.14
+104.7%
17.5%US$17.81US$8.57US$1.4829
May ’24US$6.31
US$11.38
+80.4%
17.5%US$18.29US$8.80US$1.6329
Apr ’24US$6.23
US$11.45
+83.9%
17.5%US$18.41US$8.86US$1.8529
Mar ’24US$7.43
US$12.88
+73.2%
24.7%US$25.27US$8.85US$2.4128
Feb ’24US$8.68
US$13.31
+53.3%
24.5%US$25.59US$8.97US$2.5928
Jan ’24US$7.15
US$12.90
+80.5%
27.7%US$26.19US$5.86US$3.7129
Dec ’23n/a
US$12.68
0%
27.7%US$25.71US$5.76n/a29

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/25 05:30
End of Day Share Price 2024/12/23 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

WuXi Biologics (Cayman) Inc. is covered by 54 analysts. 25 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Linda LuBOCI Research Ltd.
Wai Chak YuenBOCI Research Ltd.
Bo LiBofA Global Research